HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Hepatitis B Antibodies

Antibodies to the HEPATITIS B ANTIGENS, including antibodies to the surface (Australia) and core of the Dane particle and those to the "e" antigens.
Also Known As:
Anti HBAg; Hepatitis B Virus Antibodies; Anti Australia Antigens; Anti Hepatitis B Antigens; Antibodies, Hepatitis B; Antigens, Anti-Australia; Antigens, Anti-Hepatitis B; B Antibodies, Hepatitis; B Antigens, Anti-Hepatitis; HBAg, Anti; Anti-Australia Antigens; Anti-HBAg; Anti-Hepatitis B Antigens
Networked: 38 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Bianciardi, Laura: 1 article (02/2022)
2. Messina, Gabriele: 1 article (02/2022)
3. Miceli, Rosalia: 1 article (02/2022)
4. Occhialini, Federico: 1 article (02/2022)
5. Pietronigro, Antonella: 1 article (02/2022)
6. Salini, Chiara: 1 article (02/2022)
7. Sartorelli, Pietro: 1 article (02/2022)
8. Abass, Elfadil: 1 article (01/2020)
9. Ader, Florence: 1 article (01/2020)
10. Balsat, Marie: 1 article (01/2020)

Related Diseases

1. Hepatitis B
02/01/1988 - "The use of hepatitis B core antibody for screening and subsequent hepatitis B vaccination of antibody-negative personnel was most cost-effective for hospitals considered to have high prevalence for hepatitis B virus antibodies among its staff, although use of hepatitis B surface antibody in this setting only increased costs by 1.4%. "
02/01/1988 - "We concluded that hepatitis B core antibody should be used for screening in hospitals with high prevalence for hepatitis B virus antibodies among employees while hepatitis B surface antibody be used for screening in hospitals with low prevalence for hepatitis B virus antibodies among employees. "
02/01/1988 - "In a hospital with low prevalence for hepatitis B virus antibodies among its staff, use of hepatitis B surface antibody and subsequent vaccination of antibody-negative individuals was the most cost-effective approach, while use of hepatitis B core antibody for the above purposes would have increased costs by 3.4%. "
02/01/1988 - "We compared the cost of antibody screening and the projected cost for hepatitis B vaccination of antibody-negative individuals at hospitals with "high prevalence" and "low prevalence" rates for hepatitis B virus antibodies among their employees. "
04/16/1987 - "We conclude that hepatitis B caused the outbreak, that about 330,000 persons may have been infected, that the hepatitis B virus carrier state was a rare consequence, and that the outbreak induced hepatitis B antibodies that appear to persist for life."
2. Chronic Hepatitis (Chronic Active Hepatitis)
3. Infections
4. Hepatitis A (Hepatitis, Infectious)
5. Hepatitis

Related Drugs and Biologics

1. Hepatitis B Surface Antigens (HBsAg)
2. Hepatitis B Antigens
3. Surface Antigens (Surface Antigen)
4. Antibodies
5. Vaccines
6. RNA (Ribonucleic Acid)
7. Immunoglobulins (Immunoglobulin)
8. Immunoglobulin G (IgG)
9. gamma-Globulins (gamma-Globulin)
10. Hepatitis A Antibodies

Related Therapies and Procedures

1. Photopheresis
2. Therapeutics
3. Drug Therapy (Chemotherapy)